Nagoya Protocol: ‘a masterpiece of ambiguity’

Since the Nagoya Protocol was implemented in October 2014, lawyers, academics, and the life sciences industry broadly have been calling upon institutions such as the European Union for guidance on how to best abide by the new regulations.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

MedTech

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

3 August 2026 The medical device maker says that a split appellate decision raises broader questions about trade secret law, jurisdiction and when the clock starts ticking on misappropriation claims.

Careers

Arnold & Porter adds firepower to ITC practice with new partner hire

3 August 2026 Appointment strengthens the firm’s expertise in US International Trade Commission proceedings and cross-border intellectual property disputes.

Pharma

USPTO director steps into Sun Pharma’s PTAB-ITC clash

31 July 2026 A director review has overturned a PTAB ruling, questioning why it diverged from an ITC decision based on the same patent claims, prior art and evidence.

More features

Insulet asks Fed Circ to rehear $59.4m trade secret reversal

Arnold & Porter adds firepower to ITC practice with new partner hire

USPTO director steps into Sun Pharma’s PTAB-ITC clash

USPTO appoints new acting commissioner for patents

European court strikes down hearing aid sensor patent

Where Big Pharma is betting big in the M&A boom

Fish & Richardson adds AI and medical device specialist

Boston Scientific overturns $42m patent verdict on appeal

Nagoya Protocol: ‘a masterpiece of ambiguity’

More on this story

Editor's picks

Editor's picks

More features